Cancer Hospital CAMS Thoracic Surgery: Lung and Esophageal Teams

What this unit is and where its reputation comes from

The Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) runs a thoracic surgery department whose own description dates the unit to 1958. Its published scope is cancer surgery of the chest rather than general thoracic care alone: lung cancer, esophageal and cardia cancer, and other chest malignancies sit at the centre of the department's work.

The department appears first in the 2023 national thoracic-surgery specialty reputation list published by Fudan. Read that carefully. It is a dated specialty reputation reference, not a current 2026 ranking, not a ranking of individual surgeons, and not a ranking of the subspecialties inside the department. It tells you the unit has been recognised within its field in China; it does not tell you that any particular operation is right for you.

For an international patient, that distinction matters. A reputation list can help you decide which hospital to ask about. It cannot answer whether your tumour is resectable, whether a minimally invasive approach is appropriate, or whether the team would accept your case. Those are clinical judgements made after the records are reviewed.

The disease directions the department documents

The department's clinical scope page lists thoracoscopic treatment directions for lung malignancy, benign lung tumours, esophageal and cardia cancer, tracheal tumours, thymoma and other mediastinal tumours, and chest-wall tumours. It also describes surgery-led combined treatment for locally advanced chest tumours.

That is a description of what the department works on, not a promise that one minimally invasive operation suits every condition on the list. Thoracoscopic approaches to a small peripheral lung lesion and to a locally advanced oesophageal tumour are different problems with different planning. The same page covers both, but the decision pathways are not interchangeable.

The department's team page adds that its work covers lung, esophageal and cardia cancer and other chest malignancies, and it documents research networks for lung and esophageal cancer plus a thoracic-investigator alliance. For a patient, the useful reading is that the unit organises itself around these two cancer types in particular, alongside mediastinal and thymic disease.

If your diagnosis is a thymoma, a mediastinal mass or a chest-wall tumor, those directions appear within the department's published scope. For a lung nodule of uncertain nature, ask what diagnosis has been established and what assessment should precede any discussion about surgery. The treating team must determine the appropriate next step.

Who leads the team, and what their documented roles are

The department description identifies He Jie as an academic core, Gao Shugeng as vice president and Xue Qi as director. These are different institutional responsibilities. A disease-focused enquiry should also identify which clinical team would review the case, rather than assume an academic leader personally handles every assessment.

He Jie's official specialist biography describes him as a member of the Chinese Academy of Sciences, chief thoracic surgeon and doctoral supervisor, and records leadership roles at the National Cancer Center, the Cancer Hospital and a national quality-control centre. His documented clinical directions are lung, esophageal and mediastinal tumours, complex surgery, minimally invasive surgery and multimodality care. His research covers molecular typing, biomarkers and translational work.

Gao Shugeng's official biography describes him as chief physician, doctoral supervisor, tenured professor at Peking Union Medical College, deputy director of the National Cancer Center and vice president of the Cancer Hospital. His documented work includes individualised strategies for locally advanced lung cancer and lung-function-preserving precise resection for early lung cancer, including segment and subsegment approaches. He leads guideline and research work.

These biographies tell you the documented interests and institutional roles of senior figures in the unit. They do not tell you who would personally review your file, and they do not establish that any named surgeon is available for a particular patient. Appointment and case allocation are matters for the hospital.

Research networks and lung-function-preserving surgery

The department documents lung and esophageal cancer research networks and a thoracic-investigator alliance. These institutional collaborations are a more specific description of its academic work than a general claim of international reputation. For a patient seeking review, a useful question is how the treating team would distinguish established care from a research option for the actual diagnosis.

Gao Shugeng's profile connects his research and guideline work with individualized strategies for locally advanced lung cancer and precise lung-function-preserving resection in early lung cancer. Those descriptions identify an area to explore with the surgeons, not a reason to choose a limited resection independently. Ask what features of the case would determine whether this direction is relevant and which alternatives the team would compare.

For a patient, research activity is relevant in a limited way. It suggests the unit works within structured treatment pathways and contributes to national guideline and quality work. It does not mean a clinical trial place exists for you, and it does not mean an experimental option is available. Trial eligibility is a separate assessment with its own criteria, and no one can promise enrolment before that assessment happens.

A reasonable question to the treating team is whether your case fits a documented standard pathway for your cancer type and stage, and whether any research option is genuinely open to you. Ask for the answer in writing if you are comparing routes.

Department recognition and named researchers’ honors

He Jie is a member of the Chinese Academy of Sciences. His official biography records that the team received the 2013 National Science and Technology Progress First Prize for esophageal-cancer standardized-treatment technologies. The year belongs to that documented team award; it is not a date for every distinction mentioned in the department's history.

Gao Shugeng's profile lists National Science and Technology Progress Second Prize and Chinese Medical Science and Technology First Prize honors without specifying their award years. The department also records national clinical-key-specialty recognition. These distinctions provide attributable academic and institutional context; they do not rank individual surgeons against each other or predict a patient's result.

Practical decisions before a resection review

The first practical question is what kind of review you are asking for. A resection review asks whether surgery is technically and clinically appropriate for your cancer, what operation would be proposed, and what the alternatives are. It is different from a general oncology opinion about systemic treatment, and different again from a pathology re-read. Knowing which question you are bringing helps the hospital route your records to the right team.

The second question is about surgical scope and alternatives. If a lung-preserving resection such as a segment or subsegment approach is mentioned in the literature, ask whether it is appropriate for your lesion's size, position and pathology, and what the trade-offs are against a larger resection. The department documents lung-function-preserving precise resection as a direction in early lung cancer; that does not make it suitable for every early lesion, and the treating surgeon decides.

The third question is about what the team needs from you. Rather than assume a fixed document list, ask which existing imaging, pathology reports and staging information would help answer your particular surgical question, how to submit them and whether language support is required. The actual requirements must be confirmed for the assessment being arranged.

The fourth question is about the treatment plan as a whole. For locally advanced chest tumours, the department describes surgery-led combined treatment. Ask how surgery would fit with other treatment, who coordinates that planning, and what would need to be confirmed before any date is set.

Finally, ask what the hospital's written plan and quote would cover, and which parts are arranged separately. Do not assume that a published reputation or a department description establishes acceptance, a named surgeon, or a particular ward.

How ChinaSpecialistCare can help with this assessment

ChinaSpecialistCare can help organise records and coordinate a thoracic-surgery assessment request around a specific lung or esophageal question. We are independent of the hospital. The receiving clinical team decides acceptance, the reviewing specialist and treatment suitability; coordination does not guarantee a named appointment, an operation or access to research treatments.

Related specialty reference